Last updated: October 14, 2026
LO/OVRAL is a legacy combined oral contraceptive containing norgestrel and ethinyl estradiol. Its commercial value declined as generic norgestrel/ethinyl estradiol products captured the market, while Pfizer’s branded product encountered manufacturing and supply disruptions. The product no longer has the commercial profile of a protected branded medicine. Current value is concentrated in low-cost generic supply, established prescribing familiarity, and residual brand recognition rather than patent exclusivity.
What is LO/OVRAL and who marketed it?
LO/OVRAL and LO/OVRAL-28 contain 0.3 mg of norgestrel and 0.03 mg of ethinyl estradiol per active tablet. The products are combination oral contraceptives used to prevent pregnancy. LO/OVRAL-28 includes 21 active tablets followed by seven inactive tablets; LO/OVRAL-21 contains 21 active tablets without the seven-tablet reminder sequence.[1]
The brand originated under Wyeth and later became part of Pfizer’s portfolio after Pfizer completed its acquisition of Wyeth in 2009.[2] The commercial franchise was mature before the acquisition, with competition from other oral contraceptives, generic equivalents, long-acting reversible contraceptives, and newer hormonal delivery systems.
| Product |
Active ingredients |
Dosage form |
Historical manufacturer or marketer |
Current commercial position |
| LO/OVRAL-21 |
Norgestrel 0.3 mg / ethinyl estradiol 0.03 mg |
Oral tablet |
Wyeth, later Pfizer |
Legacy branded product |
| LO/OVRAL-28 |
Norgestrel 0.3 mg / ethinyl estradiol 0.03 mg |
Oral tablet pack |
Wyeth, later Pfizer |
Legacy branded product with historical supply disruption |
| Cryselle-28 |
Norgestrel 0.3 mg / ethinyl estradiol 0.03 mg |
Oral tablet pack |
Generic manufacturers |
Generic substitute |
| Low-Ogestrel-28 |
Norgestrel 0.3 mg / ethinyl estradiol 0.03 mg |
Oral tablet pack |
Generic manufacturers |
Generic substitute |
The active progestin is often described as norgestrel, although norgestrel contains the active levonorgestrel stereoisomer. Generic products are generally marketed under norgestrel and ethinyl estradiol labeling rather than under the LO/OVRAL brand.
When did LO/OVRAL lose exclusivity?
LO/OVRAL’s commercial exclusivity ended decades ago. The product is a small-molecule oral contraceptive with no current market protection comparable to a new molecular entity, biologic, or recently approved delivery system.
The original regulatory approval predated the modern Hatch-Waxman framework. Generic equivalents subsequently entered through abbreviated new drug applications, creating direct substitution and formulary pressure. The FDA Orange Book lists approved generic equivalents and associated reference products, but it does not provide a current economic valuation for the LO/OVRAL brand.[3]
LO/OVRAL exclusivity timeline
| Period |
Commercial event |
Financial effect |
| Early product lifecycle |
LO/OVRAL marketed as a branded combined oral contraceptive |
Brand pricing and physician familiarity supported revenue |
| Generic entry period |
Norgestrel/ethinyl estradiol equivalents launched |
Pricing and prescription share shifted to generics |
| 2009 |
Pfizer acquired Wyeth |
Product entered Pfizer’s established-products portfolio |
| 2012 |
Pfizer recalled multiple LO/OVRAL-28 lots after packaging and tablet-count issues |
Sales interruption and reduced confidence in supply reliability |
| Post-2012 |
Generic alternatives remained available |
Brand recovery became commercially difficult |
| Current market |
Generic norgestrel/ethinyl estradiol products dominate accessible supply |
Brand-specific revenue is limited or not separately disclosed |
What happened to LO/OVRAL supply and FDA status?
In January 2012, Pfizer recalled multiple lots of LO/OVRAL-28 and generic-equivalent products manufactured at the same facility after some packages contained an incorrect number of active or inactive tablets. The FDA warned that packaging errors could result in patients receiving an inadequate dose and could increase the risk of unintended pregnancy.[4]
The recall was commercially significant because oral contraceptive use depends on uninterrupted daily dosing. A supply event can cause patients and prescribers to switch permanently to another brand or generic, especially when therapeutically interchangeable alternatives are available.
The FDA’s current product databases and labeling records distinguish between historical approval, active marketing, and discontinued commercial status. LO/OVRAL is generally treated as a legacy product rather than a growth brand. The relevant commercial market is the broader norgestrel/ethinyl estradiol category, not the LO/OVRAL label alone.[5]
How large is the LO/OVRAL market?
No publicly reported Pfizer financial statement provides a standalone revenue line for LO/OVRAL. Pfizer reports by business segment and major product categories, while legacy oral contraceptives are generally grouped within broader established-product portfolios.[2]
The financial trajectory can therefore be assessed through market structure rather than a disclosed product-level revenue series.
Market dynamics
The primary forces affecting LO/OVRAL were:
- Generic substitution. Pharmacists, insurers, and public programs generally favor lower-cost equivalents when therapeutic substitution is allowed.
- Low switching costs. Patients can move among combined oral contraceptives with similar estrogen and progestin components.
- Contraceptive competition. Oral tablets compete with intrauterine systems, contraceptive implants, injections, patches, rings, progestin-only pills, and over-the-counter emergency contraception.
- Reimbursement pressure. Public and commercial formularies typically place mature oral contraceptives in low-cost generic tiers.
- Manufacturing reliability. The 2012 recall weakened the brand’s supply position at a point when generic substitution was already available.
- Limited innovation. The formulation did not provide a delivery-system advantage or a new active ingredient capable of supporting premium pricing.
The category remains commercially important because oral contraceptives have a large user base. That category demand does not translate into equivalent brand demand for LO/OVRAL. Value migrated from the brand owner to generic manufacturers, distributors, pharmacies, and payers.
What is the revenue trajectory for LO/OVRAL?
The likely revenue trajectory is a standard mature-brand decline:
- Initial growth came from branded prescribing and established physician familiarity.
- Revenue weakened after generic equivalents became available.
- Pfizer’s acquisition of Wyeth placed LO/OVRAL in a mature-product portfolio rather than a strategic growth franchise.
- The 2012 recall caused a direct interruption in sales and created a permanent switching risk.
- Subsequent demand shifted toward generic norgestrel/ethinyl estradiol products.
- Current brand-specific revenue is likely immaterial relative to Pfizer’s consolidated sales and is not separately disclosed.
The economic profile differs from a protected specialty drug. LO/OVRAL has no evident basis for premium pricing, no meaningful data-exclusivity runway, and no disclosed late-stage lifecycle program. Any continuing revenue would depend on residual brand demand, distribution availability, or a niche prescriber preference.
What patents protect LO/OVRAL?
LO/OVRAL does not appear to have a commercially meaningful active patent estate protecting the core tablet composition in the United States.
The combination of norgestrel and ethinyl estradiol is an old formulation. Patent-based barriers that might support a modern branded contraceptive, such as a new molecular entity, novel release mechanism, transdermal system, intrauterine device, or proprietary packaging technology, are not central to LO/OVRAL’s current market position.
Patent and regulatory protection assessment
| Protection type |
LO/OVRAL position |
Commercial relevance |
| Core composition patent |
Historical protection, if any, has expired |
No current barrier to generic entry |
| New molecular entity exclusivity |
Not applicable to this legacy combination |
None |
| Pediatric exclusivity |
No current strategic relevance |
None |
| Orphan-drug exclusivity |
Not applicable |
None |
| Formulation patent |
No current commercially material barrier identified |
Low |
| Method-of-use patent |
No meaningful current barrier identified |
Low |
| Manufacturing patent |
Any historic rights would not block standard generic manufacture |
Low |
| Orange Book patent listing |
No current brand-protection value comparable to newer products |
Low |
What formulations are protected by LO/OVRAL?
The commercially relevant formulation is an immediate-release oral tablet containing norgestrel and ethinyl estradiol. LO/OVRAL-21 and LO/OVRAL-28 differ primarily in packaging and dosing presentation rather than in a technologically differentiated delivery system.[1]
The absence of an extended-release mechanism, specialized coating, implant, ring, patch, or device component limits the ability to establish formulation-based exclusivity. Generic manufacturers can compete through substantially equivalent tablets and packaging configurations.
The principal historical product risk was packaging accuracy. The 2012 recall involved incorrect tablet counts or tablet placement in some blister packs, demonstrating that packaging control was commercially important even though packaging did not create durable intellectual-property protection.[4]
Are there Paragraph IV challenges to LO/OVRAL?
Paragraph IV litigation is not a material current risk for LO/OVRAL because the product’s principal market protections expired long ago and generic versions are already established.
A Paragraph IV certification challenges the validity, enforceability, or infringement of a listed patent in an abbreviated new drug application. That mechanism is most relevant when a branded product has an active Orange Book patent blocking generic approval. LO/OVRAL’s market has already passed that stage.
The meaningful competitive question is not whether a first generic entrant will launch. It is whether existing generic manufacturers can maintain supply, obtain favorable reimbursement, and compete on price and distribution.
Which companies compete with LO/OVRAL?
LO/OVRAL competes with generic suppliers of norgestrel/ethinyl estradiol and with other combined oral contraceptives.
Direct generic competition
The closest substitutes include:
- Cryselle-28
- Low-Ogestrel-28
- Norgestrel and ethinyl estradiol tablets marketed under generic labels
- Other approved equivalents listed against the relevant reference product in FDA databases
Broader contraceptive competition
The broader market includes:
- Levonorgestrel/ethinyl estradiol products
- Norethindrone/ethinyl estradiol products
- Desogestrel/ethinyl estradiol products
- Drospirenone/ethinyl estradiol products
- Progestin-only pills
- Vaginal rings
- Transdermal patches
- Depot injections
- Hormonal intrauterine systems
- Contraceptive implants
The strongest substitution pressure comes from low-cost oral alternatives and long-acting contraceptive methods. Product choice is influenced by adverse-effect profiles, adherence, access, clinician preference, insurance coverage, and patient willingness to use a device.
What generic entry risks exist for LO/OVRAL?
Generic entry risk is effectively realized rather than prospective. The principal risk is continued erosion of any remaining brand demand.
| Risk |
Probability |
Impact |
| Additional generic price competition |
High |
High |
| Brand-to-generic substitution |
High |
High |
| Supply interruption |
Medium |
High |
| Formulation redesign by the brand owner |
Low |
Medium |
| Paragraph IV patent challenge |
Low |
Low |
| Biosimilar competition |
Not applicable |
None |
| Reimbursement exclusion |
High |
High |
| Patient migration to long-acting contraception |
Medium |
Medium |
Biosimilar risk does not apply because LO/OVRAL is a chemically synthesized small-molecule tablet, not a biologic. The relevant regulatory pathway is the ANDA pathway, not the biosimilar pathway under the Public Health Service Act.[6]
What is the Orange Book status of LO/OVRAL?
The Orange Book is relevant because it identifies approved drug products, reference-listed drugs, therapeutic equivalents, and listed patents where applicable. For LO/OVRAL, the practical Orange Book issue is generic equivalence rather than active patent enforcement.[3]
A current commercial assessment should distinguish:
- Historical LO/OVRAL approval records
- Whether a specific national drug code remains marketed
- The reference-listed drug designation
- Active generic approvals
- Discontinued product records
- Any remaining patent listing attached to the relevant reference product
A discontinued brand record does not eliminate the broader generic market. It indicates that the branded product itself may no longer be actively supplied or promoted.
What litigation affected LO/OVRAL?
The most material publicly documented event was the 2012 product recall and related regulatory communications concerning packaging errors. That event was operational rather than patent-driven.[4]
There is no established current patent-litigation issue that supports a meaningful barrier to generic competition. Any historical commercial disputes would have limited present value unless they altered approval status, generic supply, or settlement restrictions.
Were there licensing deals for LO/OVRAL?
No major current licensing transaction is central to the LO/OVRAL investment case. The relevant corporate transaction was Pfizer’s acquisition of Wyeth, which transferred the product into Pfizer’s portfolio.[2]
That transaction should not be interpreted as a product-specific licensing arrangement or as evidence of renewed investment in LO/OVRAL. The product was acquired as part of a broad pharmaceutical portfolio containing mature brands, biologics, vaccines, and other assets.
How strong is the LO/OVRAL patent estate?
The patent estate is weak for current commercial purposes.
| Factor |
Assessment |
| Core composition protection |
Expired or commercially ineffective |
| Formulation differentiation |
Limited |
| Delivery-system protection |
None material |
| Method-of-use protection |
No meaningful current barrier |
| Generic substitution resistance |
Low |
| Manufacturing complexity |
Low to moderate |
| Regulatory exclusivity |
Expired |
| Litigation leverage |
Low |
| Pricing power |
Low |
Manufacturing does not create a substantial barrier because the dosage form is a conventional oral tablet and the active ingredients are established synthetic compounds. Competitive advantage depends more on regulatory compliance, procurement, quality systems, distribution, and cost control than on proprietary technology.
How does LO/OVRAL compare with newer contraceptive products?
| Attribute |
LO/OVRAL |
Newer branded contraceptives |
| Active ingredients |
Established estrogen-progestin combination |
May use newer progestins or delivery technologies |
| Dosage form |
Conventional oral tablet |
Tablet, ring, patch, implant, injection, or intrauterine system |
| Patent position |
Weak or expired |
May include active composition, formulation, or device patents |
| Generic exposure |
High |
Varies by product age |
| Pricing power |
Low |
Higher before generic entry |
| Adherence profile |
Daily dosing |
Some alternatives require weekly, monthly, or multi-year dosing |
| Manufacturing barrier |
Conventional tablet production |
May involve device, sterility, or specialized manufacturing |
| Revenue outlook |
Mature and declining |
Depends on launch stage and exclusivity |
LO/OVRAL’s principal disadvantage is that it combines a mature active-ingredient profile with daily adherence requirements and no durable patent protection. Its main advantage is familiarity, established clinical use, and availability of low-cost equivalent products.
Key Takeaways
- LO/OVRAL is a legacy combined oral contraceptive containing norgestrel and ethinyl estradiol.
- Pfizer inherited the product through its 2009 acquisition of Wyeth.
- Generic competition eliminated meaningful brand exclusivity long ago.
- The 2012 LO/OVRAL-28 recall created supply disruption and encouraged switching to alternatives.
- No standalone LO/OVRAL revenue figure is publicly reported by Pfizer.
- The current economic market is the generic norgestrel/ethinyl estradiol category, not the legacy brand.
- Paragraph IV, biosimilar, and active patent risks are not material to the current product.
- The remaining commercial risks are generic price competition, formulary exclusion, supply reliability, and substitution by other contraceptive methods.
- The patent estate and manufacturing barriers are weak for current market purposes.
- LO/OVRAL has little evidence of a credible revenue recovery path absent a new formulation, delivery system, or commercial relaunch.
FAQs About LO/OVRAL Market Value and Exclusivity
Is LO/OVRAL still sold in the United States?
LO/OVRAL is generally treated as a legacy or discontinued branded product in U.S. commercial analysis. Generic norgestrel/ethinyl estradiol products remain the relevant substitutes.
Is Cryselle the same as LO/OVRAL?
Cryselle contains the same stated active ingredients and strengths as LO/OVRAL-28: norgestrel 0.3 mg and ethinyl estradiol 0.03 mg. It is marketed as a generic equivalent rather than as the LO/OVRAL brand.
Does LO/OVRAL have biosimilar competition?
No. Biosimilars compete with biologic medicines. LO/OVRAL is a conventional small-molecule oral tablet and competes with generic drug products approved through the ANDA pathway.
Can Pfizer relaunch LO/OVRAL at a premium price?
A relaunch would face substantial obstacles, including generic availability, low switching costs, weak patent protection, and limited formulation differentiation. A premium relaunch would require a meaningful delivery, adherence, packaging, or clinical-positioning advantage.
What is the investment thesis for LO/OVRAL?
The product does not present a conventional branded-drug growth thesis. Any residual value is tied to generic-category demand, manufacturing efficiency, distribution rights, or portfolio rationalization rather than to patent-backed pricing power.
References
-
Pfizer Inc. (2011). LO/OVRAL-28 and LO/OVRAL-21 prescribing information. U.S. Food and Drug Administration labeling database.
-
Pfizer Inc. (2009). Pfizer completes acquisition of Wyeth. Pfizer investor and corporate materials.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (2012). Pfizer recall of LO/OVRAL-28 and generic norgestrel/ethinyl estradiol tablets due to packaging errors. FDA Drug Safety Communication.
-
U.S. Food and Drug Administration. (2024). Drugs@FDA and National Drug Code Directory. FDA.
-
U.S. Food and Drug Administration. (2024). Abbreviated new drug application process and generic drug approval standards. FDA.
